Literature DB >> 16221997

Anhedonia in schizophrenia: a review of assessment strategies.

William P Horan1, Ann M Kring, Jack J Blanchard.   

Abstract

Anhedonia, the diminished capacity to experience pleasant emotions, is a common, treatment-resistant feature of schizophrenia that is often included among the negative symptoms of this disorder. This selective review describes the 3 most commonly used approaches to assess anhedonia in schizophrenia: interview-based measures, self-report trait questionnaires, and laboratory-based assessments of emotional experience. For each assessment approach, psychometric properties, relationships to other symptoms and features of schizophrenia, and relationships with the other assessment approaches are evaluated. It is concluded that anhedonia can be reliably assessed and constitutes a distinctive, clinically important aspect of schizophrenia that should be included in a comprehensive evaluation of negative symptoms. Current efforts to define more precisely the nature of the hedonic deficit in schizophrenia are discussed, and recommendations for optimal assessment of anhedonia in clinical trials of novel treatments for negative symptoms are provided.

Entities:  

Mesh:

Year:  2005        PMID: 16221997      PMCID: PMC2632206          DOI: 10.1093/schbul/sbj009

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  125 in total

1.  Working memory and Wisconsin Card Sorting Test performance in schizotypic individuals: a replication and extension.

Authors:  K A Tallent; D C Gooding
Journal:  Psychiatry Res       Date:  1999-12-27       Impact factor: 3.222

Review 2.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

3.  A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

Authors:  R P Snaith; M Hamilton; S Morley; A Humayan; D Hargreaves; P Trigwell
Journal:  Br J Psychiatry       Date:  1995-07       Impact factor: 9.319

4.  Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders.

Authors:  V Peralta; M J Cuesta
Journal:  Schizophr Res       Date:  1999-07-27       Impact factor: 4.939

5.  Relations among clinical scales in schizophrenia.

Authors:  R E Gur; P D Mozley; S M Resnick; S Levick; R Erwin; A J Saykin; R C Gur
Journal:  Am J Psychiatry       Date:  1991-04       Impact factor: 18.112

Review 6.  Schizophrenia: the characteristic symptoms.

Authors:  N C Andreasen; M Flaum
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

7.  Temporal course of emotional startle modulation in schizophrenia patients.

Authors:  Martin Volz; Alfons O Hamm; Peter Kirsch; Eibe-Rudolf Rey
Journal:  Int J Psychophysiol       Date:  2003-08       Impact factor: 2.997

8.  On the broad applicability of the affective circumplex: representations of affective knowledge among schizophrenia patients.

Authors:  Ann M Kring; Lisa Feldman Barrett; David E Gard
Journal:  Psychol Sci       Date:  2003-05

Review 9.  Schizophrenia and personality: exploring the boundaries and connections between vulnerability and outcome.

Authors:  H Berenbaum; F Fujita
Journal:  J Abnorm Psychol       Date:  1994-02

10.  The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms.

Authors:  Hans-Jürgen Möller; Ronald Bottlender; Anke Gross; Paul Hoff; Johannes Wittmann; Ulrike Wegner; Anton Strauss
Journal:  Schizophr Res       Date:  2002-07-01       Impact factor: 4.939

View more
  113 in total

Review 1.  Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity.

Authors:  Adam M Leventhal; Michael J Zvolensky
Journal:  Psychol Bull       Date:  2014-11-03       Impact factor: 17.737

2.  The challenges of fitting an item response theory model to the Social Anhedonia Scale.

Authors:  Steven P Reise; William P Horan; Jack J Blanchard
Journal:  J Pers Assess       Date:  2011-05

Review 3.  A new perspective on anhedonia in schizophrenia.

Authors:  Gregory P Strauss; James M Gold
Journal:  Am J Psychiatry       Date:  2012-04       Impact factor: 18.112

4.  The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia.

Authors:  Eri Nakagami; Maanse Hoe; John S Brekke
Journal:  Schizophr Bull       Date:  2010-05-12       Impact factor: 9.306

Review 5.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

Review 6.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

7.  Behavioral approach and avoidance in schizophrenia: an evaluation of motivational profiles.

Authors:  L Felice Reddy; Michael F Green; Shemra Rizzo; Catherine A Sugar; Jack J Blanchard; Raquel E Gur; Ann M Kring; William P Horan
Journal:  Schizophr Res       Date:  2014-08-19       Impact factor: 4.939

8.  Social Disconnection in Schizophrenia and the General Community.

Authors:  Michael F Green; William P Horan; Junghee Lee; Amanda McCleery; L Felice Reddy; Jonathan K Wynn
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

9.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 10.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.